PAMAM Nanoparticle Degrades MDM2 and GLUT1 Proteins
Summary
USPTO publishes patent application US20260108474A1 for a PAMAM-based nanoparticle protein degradation system targeting MDM2 and GLUT1 proteins for cancer therapy. Invented by Yingshu Guo and Wennan Yan, the system uses silica nanoparticle cores coated with poly(amidoamine) dendrimers linked to three small-molecule ligands. Filed December 19, 2025 and published April 23, 2026, the application claims a cooperative degradation strategy that suppresses tumor cell proliferation and stabilizes p53 protein.
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 219 changes logged to date.
What changed
USPTO published patent application US20260108474A1 disclosing a PAMAM dendrimer nanoparticle system designed to cooperatively degrade MDM2 and GLUT1 proteins for cancer therapy. The system comprises a silica nanoparticle core coated with poly(amidoamine) dendrimers linked to three ligands: Idasanutlin (MDM2), Lavendustin B (GLUT1), and Thalidomide-NH-CH2-COOH (E3 ubiquitin ligase). The cooperative degradation approach simultaneously suppresses tumor cell energy metabolism and stabilizes p53 protein to inhibit tumor growth.
Pharmaceutical and biotechnology companies developing targeted protein degradation therapies or nanoparticle-based cancer treatments should monitor this application for potential freedom-to-operate implications. The inventors claim a novel multi-target degradation strategy combining oncogenic protein suppression with p53 stabilization, an approach that could inform future cancer therapeutic development programs and patent landscape analysis.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
PAMAM-BASED NANOPARTICLE PROTEIN DEGRADATION SYSTEM AND METHOD OF PREPARATION AND USE THEREOF
Application US20260108474A1 Kind: A1 Apr 23, 2026
Inventors
Yingshu GUO, Wennan YAN
Abstract
A PAMAM-based protein degradation system and a method of preparation and use thereof are provided. The protein degradation system comprises: a silica nanoparticle core; and a poly(amidoamine) dendrimer (PAMAM) layer coated on a surface of the silica nanoparticle, wherein the PAMAM layer is linked via amide bonds to three small-molecule ligands: MDM2 protein ligand Idasanutlin, GLUT1 protein ligand Lavendustin B and E3 ubiquitin ligase ligand Thalidomide-NH—CH2—COOH. The nanoparticle protein degradation system cooperatively degrades MDM2 protein and GLUT1 protein. This cooperative degradation strategy not only effectively suppresses proliferation and energy metabolism of tumor cells, but also significantly enhances the stability of p53 protein. By restoring the normal function of p53 protein, tumor cell growth is further inhibited, providing a new strategy for cancer therapy.
CPC Classifications
A61K 9/5146 A61K 9/5115 A61K 9/5192 A61K 47/542 A61K 47/545 A61K 47/59 A61K 47/6923 A61P 35/00
Filing Date
2025-12-19
Application No.
19426262
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.